Clene

Yahoo Finance • last month

Clene files to sell 491,496 shares of common stock by selling shareholders

* Clene (NASDAQ:CLNN [https://seekingalpha.com/symbol/CLNN]) filed to sell 491,496 million shares of common stock. * The company will not receive any proceeds from the sale of common stock by the selling shareholder. * Filing [https:... Full story

Yahoo Finance • last month

Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease

Novel human preclinical neuronal model for Parkinson’s disease demonstrated CNM-Au8’s ability to improve mitochondrial health, restore cellular metabolism, reduce inflammation, and normalize dysregulated gene expression in both familial an... Full story

Yahoo Finance • 2 months ago

Presenting on Emerging Growth Conference 85 Day 2 on August 21; Register to live stream

MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth Conference identifies co... Full story

Yahoo Finance • 2 months ago

Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream

MIAMI, Aug. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth Conference identifies co... Full story

Yahoo Finance • 2 months ago

Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights

Following constructive FDA feedback on its proposed statistical analysis plan, Clene plans to analyze the neurofilament light data from its large NIH-sponsored Early Access Protocol early in the fourth quarter of 2025A second Type C meetin... Full story

Yahoo Finance • 2 months ago

Clene to Present at the Canaccord 45th Annual Growth Conference

SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolu... Full story

Yahoo Finance • 3 months ago

Presenting on Emerging Growth Conference 84 Day 2 on July 17; Register to live stream

MIAMI, July 16, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 84th Emerging Growth Conference on July 16 & 17, 2025. The Emerging Growth Conference identifies comp... Full story

Yahoo Finance • 3 months ago

Presenting on Emerging Growth Conference 84 Day 1 on July 16; Register to live stream

MIAMI, July 15, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 84th Emerging Growth Conference on July 16 & 17, 2025. The Emerging Growth Conference identifies comp... Full story

Yahoo Finance • 3 months ago

Clene files prospectus supplement for $2 million stock offering under existing agreement

Clene Inc. (NASDAQ:CLNN), currently trading at $3.90 per share with a market capitalization of $35.48 million, announced Thursday that it has filed a prospectus supplement to offer and sell up to $2,015,000 of additional shares of its com... Full story

Yahoo Finance • 3 months ago

Clene stock advances as FDA meetings approach for ALS treatment

Investing.com - Clene Inc. (NASDAQ:CLNN), a $35.6 million market cap biotech company, has completed a Type-C meeting with the FDA regarding its CNM-Au8 treatment for amyotrophic lateral sclerosis (ALS), the company announced Tuesday. Acc... Full story

Yahoo Finance • 3 months ago

Clene stock maintains Buy rating at H.C. Wainwright on ALS drug progress

Investing.com - H.C. Wainwright has reiterated its Buy rating and $31.00 price target on Clene , Inc. (NASDAQ:CLNN), representing significant upside from the current price of $3.91. The bullish stance comes as the company updates its CNM-... Full story

Yahoo Finance • 5 months ago

Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream

MIAMI, May 21, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies compan... Full story

Yahoo Finance • 5 months ago

Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream

MIAMI, May 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies compan... Full story

Yahoo Finance • 6 months ago

Clene to Present at the Emerging Growth Conference

SALT LAKE CITY, April 14, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to advancin... Full story

Yahoo Finance • 7 months ago

Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment

SALT LAKE CITY, March 12, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases... Full story

Yahoo Finance • 7 months ago

Clene to Present at the 37TH Annual Roth Conference

SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revol... Full story

Yahoo Finance • 2 years ago

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases

Clene Inc. Journal of Nanobiotechnology publication describes results from the successful Phase 2 REPAIR clinical studies that measured changes in brain energy metabolites in multiple sclerosis and Parkinson’s disease with CNM-Au8® treatm... Full story

Yahoo Finance • 2 years ago

Clene's Long-Term Follow-Up Data Shows Significantly Improved Survival in ALS Patients

LOS ANGELES, CA - (NewMediaWire) - December 12, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company. Clene (NASDAQ: CLNN), together with its w... Full story

Yahoo Finance • 2 years ago

Clene Among Grant Awardees Selected to Advance Scientific Research on ALS

LOS ANGELES, CA - (NewMediaWire) - November 14, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company. Clene, a company targeting the treatment... Full story

Yahoo Finance • 2 years ago

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

Reported statistically significant improved survival benefit of 19.3 months and significantly delayed clinical worsening in patients treated with CNM-Au8® in the RESCUE ALS open-label extension trialReported statistically significant long-... Full story